Application of Circulating Tumor Cell (CTC) PD-L1 Detection in the Evaluation of Therapeutic Efficacy in Advanced NSCLC: A Retrospective Study

被引：0
|
作者：
Deng, Y. [1 ]
Huang, Y. [2 ]
Cai, S. [1 ]
Yu, Z. [1 ]
Guo, X. [1 ]
机构：
[1] Shenzhen Canc Hosp, Shenzhen, Peoples R China
[2] Cell Shenzhen, Shenzhen, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
NSCLC; circulating tumor cell; immunotherapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.11A.11
引用
收藏
页码：S600 / S600
页数：1
相关论文
共 50 条
  • [41] Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer
    Ilie, M.
    Szafer-Glusman, E.
    Hofman, V.
    Chamorey, E.
    Lalvee, S.
    Selva, E.
    Leroy, S.
    Marquette, C. -H.
    Kowanetz, M.
    Hedge, P.
    Punnoose, E.
    Hofman, P.
    ANNALS OF ONCOLOGY, 2018, 29 (01) : 193 - 199
  • [42] Detection of PD-L1 positive circulating tumor cells from patient with bladder cancer
    Suh, Yongjoon
    Kim, Seong-Kun
    Lee, Hye Seon
    Jeong, Yun-Gyu
    Moon, Jeong-Mi
    Kim, Myoung Shin
    Jeon, Byung Hee
    Ha, U-Syn
    CANCER RESEARCH, 2019, 79 (13)
  • [43] Method development for detection of PD-L1 in circulating tumor cells in small-cell lung cancer patients
    Cheng, Ying
    Li, Hui
    Zhao, Dandan
    Liu, Yan
    Wang, Ying
    Liu, Xianhong
    Cui, Hongxia
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [44] From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
    Zhao, Xuan
    Bao, Yulin
    Meng, Bi
    Xu, Zijian
    Li, Sijin
    Wang, Xu
    Hou, Rui
    Ma, Wen
    Liu, Dan
    Zheng, Junnian
    Shi, Ming
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [45] The association between BIM deletion polymorphism and treatment efficacy of PD-1/PD-L1 inhibitors in advanced NSCLC.
    Zhang, Dai
    Li, Xuanzong
    Huang, Caimei
    Fan, Xinyu
    Qin, Wenru
    Yang, Linlin
    Wang, Linlin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] Circulating tumor cell assay to non-invasively evaluate PD-L1 and other therapeutic targets in multiple cancers
    Page, Raymond
    Patil, Darshana
    Akolkar, Dadasaheb
    Murthy, Sudha S.
    Bendale, Kiran
    Patil, Revati
    Fulmali, Pradeep
    Fulmali, Pooja
    Adhav, Archana
    Puranik, Sneha
    Apurwa, Sachin
    Datta, Vineet
    Bose, Chirantan
    Schuster, Stefan
    John, Jinumary
    Srinivasan, Ajay
    Datar, Rajan
    PLOS ONE, 2022, 17 (06):
  • [47] Isolation of circulating tumor cells and evaluation of PD-L1 expression in metastatic lung cancer
    Dhar, Manjima
    Che, James
    Wong, Jessica M.
    Pao, Edward
    Yu, Victor S. H.
    Matsumoto, Melissa
    Goldman, Jonathan
    Garon, Edward
    Sollier, Elodie
    Kulkarni, Rajan
    Di Carlo, Dino
    CANCER RESEARCH, 2015, 75
  • [48] Differential expression of PD-L1 on circulating tumor cells among patients with advanced lung cancer
    Kim, Woong
    Koh, Yasuhiro
    Akamatsu, Hiroaki
    Yagi, Satomi
    Tanaka, Ayaka
    Kanai, Kuninobu
    Hayata, Atsushi
    Shibaki, Ryota
    Higuchi, Masayuki
    Kanbara, Hisashige
    Kikuchi, Takashi
    Akamatsu, Keiichiro
    Nakanishi, Masanori
    Ueda, Hiroki
    Yamamoto, Nobuyuki
    CANCER RESEARCH, 2016, 76
  • [49] PD-L1 in circulating exosomes of Merkel cell carcinoma
    Zanella, Anais
    Vautrot, Valentin
    Aubin, Francois
    Avoscan, Laure
    Samimi, Mahtab
    Garrido, Carmen
    Gobbo, Jessica
    Nardin, Charlee
    EXPERIMENTAL DERMATOLOGY, 2022, 31 (06) : 869 - 877
  • [50] Efficacy and safety of the PD-1/PD-L1 in metastasic non-small cell lung cancer (NSCLC)
    Gonzalez-Velez, Abel
    Pino-Villareal, Luis E.
    Barrera-Barinas, Alexander
    Castillo-Niuman, Andrea
    Tolosa-Perez, Erica N.
    Castelblanco, Diana, I
    Pinzon-Florez, Carlos E.
    Yomayusa, Nancy
    GACETA MEXICANA DE ONCOLOGIA, 2021, 20 (03): : 111 - 123
12345